FOLFOX和FOLFIRI方案用于大肠黏液腺癌辅助化疗的比较

Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma

目的 探讨FOLFOX及FOLFIRI方案在大肠黏液腺癌术后辅助化疗中的疗效差异。方法 将40例术后病理证实为大肠黏液腺癌患者随机分为2组，实验组应用FOLFIRI方案化疗，对照组应用FOLFOX方案化疗。比较两组的无进展生存时间（progressionfreesurvival，PFS），并应用Kaplan-Meier法进行生存率统计分析。结果 FOLFOX组的中位PFS为13个月，FOLFIRI组的中位PFS为18个月。FOLFIRI方案组PFS比FOLFOX方案组PFS长5个月，差异有统计学意义（χ2=4.294，P=0.038）。结论对于大肠黏液腺癌，术后应用FOLFIRI方案化疗比FOLFOX方案可延长PFS。

Objective To evaluate the clinical effect of FOLFOX regimen and FOLFIRI regimenin the treatment of colorectal mucinous adenocarcinoma after operation. Methods 40 patients confirmedmucinous adenocarcinoma by surgery and pathology were divided randomly into two groups. Twenty patients(Group FOLFOX) were treated with oxaliplatin combined with 5-fluorouracil, while the other Twenty patients(Group FOLFIRI) were treated with irinotecan combined with 5-fluorouracil. The progression free survival(PFS) of two groups was compared. Survival was estimated using the Kaplan-Meier method. Results ThePFS of Group FOLFOX is 13 months, while the PFS of Group FOLFIRI is 18 months. Differences arestatistically significant (χ2=4.294, P=0.038). Conclusion Colorectal mucinous adenocarcinoma afteroperation treated with FOLFIRI regimen can prolong PFS than FOLFOX regimen.